Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.

Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days

Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days

COVID19

After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment
Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment

Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment
Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment

Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Standard treatment

Faculty of Medicine, Kafr El-sheikh University

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized)

Isotretinoin in Treatment of COVID-19 (Randomized)

Proportion of lung injury score decreased or increased after treatment

Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon

less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample

Mahmoud Ramadan mohamed Elkazzaz

Sponser Investigator

Kafrelsheikh University

Patients and method :
This study will performed on 1000 patients tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection will randomly divided into 3 equal groups

Patients
This study will performed on 1000 patients tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection will randomly divided into 3 equal groups

2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg

Dyslipidemias

Cardiovascular Risk Factor

Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.

L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg

Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.

Atorvastatin 10mg

World Health Organization: Global Status report on non-communicable diseases 2014.

Diagnostic and Treatments od the Dyslipidemias (Hypercholesterolemia) in adults. México, 2016.

Protocolo clínico para el diagnóstico y tratamiento de las Dislipidemias. CENAPRECE, Secretaría e Salud, D.F. México.

Treatment of lipids (including hypercholesterolemia) in secondary prevention.

Detección y Estratificación de Factores de Riesgo Cardiovascular. México, 2010.

Organization for Economic Cooperation and Development.

Laboratorios Grossman Sa

Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Evaluate the change of atorvastatin + l-carnitine vs. atorvastatin alone for dyslipidemia, through change of C-LDL in mg/dl

Evaluate the change of Cholesterol no-HDL in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

Evaluate the change of serum levels of Cholesterol in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

Evaluate the reduction of serum levels of Triglycerides in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

Evaluate the change of serum levels of Cholesterol HDL in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

Evaluate the incidence, of serious and non-serious adverse events related through the oral route administration of L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment in the subjects participating in the study

Laboratorios Grossman, S.A.

Instituto Nacional de Salud Publica, Mexico

Sweat will be collected from inflammatory and neoplastic skin lesions with an FDA approved diagnostic skin patch for analysis with mass spectrometry

Application Site Perspiration

Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.

Skin Patch

Hollywood Dermatology

Proteomic Analysis of Sweat in Cutaneous Conditions

Proteomic Analysis of Sweat in Cutaneous Inflammatory and Neoplastic Conditions

Mass spectrometry will be used to identify protein fragments from sweat collected from a skin patch that will be applied directly to skin lesions of eczema, psoriasis, granuloma annulare, cutaneous lymphoma, basal cell carcinoma, squamous cell carcinoma and melanoma. These protein fragments will be compared to protein fragments perspired from normal skin in order to look for signature patterns of expression that correlate to each disease entity. Low abundance labile sweat protein fragments harvested from the nanoparticles will be measured by clinical immunoassays to verify sensitivity and precision.

melanoma/protease

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized)

Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

Proteomic Analysis of Sweat in Cutaneous Conditions

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen